Private Capital Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Private Capital Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-358	Closed	-$6K	–	2240
2019 Q2	$6K	Sell	358 -58	-14%	-$593	﹤0.01%	1569
2019 Q1	$6K	Buy	416 +361	+656%	+$4.77K	﹤0.01%	1598
2018 Q4	$1K	Sell	55 -410	-88%	-$7.39K	﹤0.01%	1990
2018 Q3	$10K	Hold	465	–	–	﹤0.01%	1444
2018 Q2	$7K	Buy	+465	New	+$8.16K	﹤0.01%	1533

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Private Capital Group's AMRX Position: Q3 2019 in Review

Private Capital Group sold out of Amneal Pharmaceuticals (AMRX) in Q3 2019, closing a stake of 358 shares — an estimated $6K sold.

Private Capital Group first reported a position in AMRX in Q2 2018 and held it in 5 quarters. The position peaked at $10K in Q3 2018. 121 funds tracked by Wall St. Rank hold AMRX as of Q3 2019.

Private Capital Group reported no remaining Amneal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Private Capital Group sold 358 Amneal Pharmaceuticals shares in Q3 2019, an estimated $6K.
Private Capital Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Private Capital Group's Amneal Pharmaceuticals position peaked at $10K in Q3 2018.
121 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2019.

Based on Private Capital Group's 13F filing for Q3 2019, filed 13 Nov 2019.